News

Lunesta (eszopiclone) is the first and only sleep aid (prescription or over-the-counter), which has been approved by the FDA for long-term treatment of insomnia. It is also the

AD 452 is a novel, small molecule, disease modifying anti-rheumatic drug (DMARD), designed to reduce joint inflammation and destruction, pain, and preserve mobility. The trial investigated the pharmacokinetics,

The FDA told Pfizer that, although Bextra’s cardiovascular risk could not be differentiated from other non-steroidal anti-inflammatory drugs (NSAIDs), the additional, increased risk of rare but serious skin

The phase II study evaluated the efficacy of Gardasil in preventing infection from the types of human papillomavirus (HPV) responsible for 70% of all cases of cervical cancer

Under the agreement, Plexxikon’s libraries will be screened in parallel against the most therapeutically relevant kinase targets among a panel of 100 enzymes available currently. Plexxikon anticipates a

The Canadian patent represents the first patent covering bioactive natural products discovered using the company’s Decipher technology. Patent applications corresponding to the issued patent are pending in the

One of the studies revealed that patients taking olanzapine (Eli Lilly’s Zyprexa) or clozapine (Novartis’ Clozaril) remained on treatment longer than other atypicals (risperidone – Johnson & Johnson’s

The Texas Pharmacy Association (TPA) has unveiled an advertising campaign and a newly created patient bill of rights. The materials, which will be delivered to 1,200 pharmacies throughout

PRO 2000 is Indevus’ microbicide under development to prevent sexually acquired HIV infection and certain other sexually transmitted disease-causing viruses and bacteria. The phase III trial is designed